Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis
Identifieur interne : 002180 ( Istex/Corpus ); précédent : 002179; suivant : 002181Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis
Auteurs : J. Risteli ; H. S Gaard ; A. Oikarinen ; L. Risteli ; J. Karvonen ; H. ZachariaeSource :
- British Journal of Dermatology [ 0007-0963 ] ; 1988-09.
Abstract
Twenty‐four psoriatic patients on methotrexate were studied with liver biopsies and serum measurements of aminoterminal propeptide of type III procollagen (PHI NP). All but one of nine patients with scrum levels of PHI NP above the normal range had liver fibrosis or cirrhosis and no normal liver biopsies were obtained in this group. In contrast, nine normal liver biopsies and two biopsies with minimal fibrosis were found among the 15 patients with normal serum levels of PHI NP. The study indicates that aminoterminal propeptide of type III procollagen can be utilized as a valuable non‐invasive marker of fibrogenesis in the liver. This analysis is not specific for the liver, but it seems that the number of liver biopsies probably can be reduced in psoriatics on methotrexate who have normal levels of PHI NP.
Url:
DOI: 10.1111/j.1365-2133.1988.tb03224.x
Links to Exploration step
ISTEX:350F372AD0F42DCE0960A56C8EF60D85E9DF046BLe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis</title><author><name sortKey="Risteli, J" sort="Risteli, J" uniqKey="Risteli J" first="J." last="Risteli">J. Risteli</name><affiliation><mods:affiliation>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</mods:affiliation></affiliation></author><author><name sortKey="S Gaard, H" sort="S Gaard, H" uniqKey="S Gaard H" first="H." last="S Gaard">H. S Gaard</name><affiliation><mods:affiliation>Department of Pathology, Aarhus Kommunehospital, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Oikarinen, A" sort="Oikarinen, A" uniqKey="Oikarinen A" first="A." last="Oikarinen">A. Oikarinen</name><affiliation><mods:affiliation>Department of Dermatology, University of Oulu, Finland</mods:affiliation></affiliation></author><author><name sortKey="Risteli, L" sort="Risteli, L" uniqKey="Risteli L" first="L." last="Risteli">L. Risteli</name><affiliation><mods:affiliation>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</mods:affiliation></affiliation></author><author><name sortKey="Karvonen, J" sort="Karvonen, J" uniqKey="Karvonen J" first="J." last="Karvonen">J. Karvonen</name><affiliation><mods:affiliation>Department of Dermatology, University of Oulu, Finland</mods:affiliation></affiliation></author><author><name sortKey="Zachariae, H" sort="Zachariae, H" uniqKey="Zachariae H" first="H." last="Zachariae">H. Zachariae</name><affiliation><mods:affiliation>Department of Dermatology, Marselisborg Hospital, University of Aarhus, Denmark</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:350F372AD0F42DCE0960A56C8EF60D85E9DF046B</idno><date when="1988" year="1988">1988</date><idno type="doi">10.1111/j.1365-2133.1988.tb03224.x</idno><idno type="url">https://api.istex.fr/document/350F372AD0F42DCE0960A56C8EF60D85E9DF046B/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002180</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis</title><author><name sortKey="Risteli, J" sort="Risteli, J" uniqKey="Risteli J" first="J." last="Risteli">J. Risteli</name><affiliation><mods:affiliation>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</mods:affiliation></affiliation></author><author><name sortKey="S Gaard, H" sort="S Gaard, H" uniqKey="S Gaard H" first="H." last="S Gaard">H. S Gaard</name><affiliation><mods:affiliation>Department of Pathology, Aarhus Kommunehospital, Denmark</mods:affiliation></affiliation></author><author><name sortKey="Oikarinen, A" sort="Oikarinen, A" uniqKey="Oikarinen A" first="A." last="Oikarinen">A. Oikarinen</name><affiliation><mods:affiliation>Department of Dermatology, University of Oulu, Finland</mods:affiliation></affiliation></author><author><name sortKey="Risteli, L" sort="Risteli, L" uniqKey="Risteli L" first="L." last="Risteli">L. Risteli</name><affiliation><mods:affiliation>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</mods:affiliation></affiliation></author><author><name sortKey="Karvonen, J" sort="Karvonen, J" uniqKey="Karvonen J" first="J." last="Karvonen">J. Karvonen</name><affiliation><mods:affiliation>Department of Dermatology, University of Oulu, Finland</mods:affiliation></affiliation></author><author><name sortKey="Zachariae, H" sort="Zachariae, H" uniqKey="Zachariae H" first="H." last="Zachariae">H. Zachariae</name><affiliation><mods:affiliation>Department of Dermatology, Marselisborg Hospital, University of Aarhus, Denmark</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">British Journal of Dermatology</title><idno type="ISSN">0007-0963</idno><idno type="eISSN">1365-2133</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1988-09">1988-09</date><biblScope unit="volume">119</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="321">321</biblScope><biblScope unit="page" to="325">325</biblScope></imprint><idno type="ISSN">0007-0963</idno></series><idno type="istex">350F372AD0F42DCE0960A56C8EF60D85E9DF046B</idno><idno type="DOI">10.1111/j.1365-2133.1988.tb03224.x</idno><idno type="ArticleID">BJD321</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0007-0963</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Twenty‐four psoriatic patients on methotrexate were studied with liver biopsies and serum measurements of aminoterminal propeptide of type III procollagen (PHI NP). All but one of nine patients with scrum levels of PHI NP above the normal range had liver fibrosis or cirrhosis and no normal liver biopsies were obtained in this group. In contrast, nine normal liver biopsies and two biopsies with minimal fibrosis were found among the 15 patients with normal serum levels of PHI NP. The study indicates that aminoterminal propeptide of type III procollagen can be utilized as a valuable non‐invasive marker of fibrogenesis in the liver. This analysis is not specific for the liver, but it seems that the number of liver biopsies probably can be reduced in psoriatics on methotrexate who have normal levels of PHI NP.</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>J. RISTELI</name><affiliations><json:string>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</json:string></affiliations></json:item><json:item><name>H. SØGAARD</name><affiliations><json:string>Department of Pathology, Aarhus Kommunehospital, Denmark</json:string></affiliations></json:item><json:item><name>A. OIKARINEN</name><affiliations><json:string>Department of Dermatology, University of Oulu, Finland</json:string></affiliations></json:item><json:item><name>L. RISTELI</name><affiliations><json:string>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</json:string></affiliations></json:item><json:item><name>J. KARVONEN</name><affiliations><json:string>Department of Dermatology, University of Oulu, Finland</json:string></affiliations></json:item><json:item><name>H. ZACHARIAE</name><affiliations><json:string>Department of Dermatology, Marselisborg Hospital, University of Aarhus, Denmark</json:string></affiliations></json:item></author><articleId><json:string>BJD321</json:string></articleId><language><json:string>eng</json:string></language><abstract>Twenty‐four psoriatic patients on methotrexate were studied with liver biopsies and serum measurements of aminoterminal propeptide of type III procollagen (PHI NP). All but one of nine patients with scrum levels of PHI NP above the normal range had liver fibrosis or cirrhosis and no normal liver biopsies were obtained in this group. In contrast, nine normal liver biopsies and two biopsies with minimal fibrosis were found among the 15 patients with normal serum levels of PHI NP. The study indicates that aminoterminal propeptide of type III procollagen can be utilized as a valuable non‐invasive marker of fibrogenesis in the liver. This analysis is not specific for the liver, but it seems that the number of liver biopsies probably can be reduced in psoriatics on methotrexate who have normal levels of PHI NP.</abstract><qualityIndicators><score>4.815</score><pdfVersion>1.6</pdfVersion><pdfPageSize>507 x 703 pts</pdfPageSize><refBibsNative>true</refBibsNative><keywordCount>0</keywordCount><abstractCharCount>816</abstractCharCount><pdfWordCount>1719</pdfWordCount><pdfCharCount>10746</pdfCharCount><pdfPageCount>6</pdfPageCount><abstractWordCount>133</abstractWordCount></qualityIndicators><title>Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis</title><genre><json:string>article</json:string></genre><host><volume>119</volume><publisherId><json:string>BJD</json:string></publisherId><pages><total>5</total><last>325</last><first>321</first></pages><issn><json:string>0007-0963</json:string></issn><issue>3</issue><genre><json:string>Journal</json:string></genre><language><json:string>unknown</json:string></language><eissn><json:string>1365-2133</json:string></eissn><title>British Journal of Dermatology</title><doi><json:string>10.1111/(ISSN)1365-2133</json:string></doi></host><publicationDate>1988</publicationDate><copyrightDate>1988</copyrightDate><doi><json:string>10.1111/j.1365-2133.1988.tb03224.x</json:string></doi><id>350F372AD0F42DCE0960A56C8EF60D85E9DF046B</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/350F372AD0F42DCE0960A56C8EF60D85E9DF046B/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/350F372AD0F42DCE0960A56C8EF60D85E9DF046B/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/350F372AD0F42DCE0960A56C8EF60D85E9DF046B/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><availability><p>WILEY</p></availability><date>1988</date></publicationStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis</title><author><persName><forename type="first">J.</forename><surname>RISTELI</surname></persName><affiliation>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</affiliation></author><author><persName><forename type="first">H.</forename><surname>SØGAARD</surname></persName><affiliation>Department of Pathology, Aarhus Kommunehospital, Denmark</affiliation></author><author><persName><forename type="first">A.</forename><surname>OIKARINEN</surname></persName><affiliation>Department of Dermatology, University of Oulu, Finland</affiliation></author><author><persName><forename type="first">L.</forename><surname>RISTELI</surname></persName><affiliation>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</affiliation></author><author><persName><forename type="first">J.</forename><surname>KARVONEN</surname></persName><affiliation>Department of Dermatology, University of Oulu, Finland</affiliation></author><author><persName><forename type="first">H.</forename><surname>ZACHARIAE</surname></persName><note type="correspondence"><p>Correspondence: Dr H.Zachariae, Department of Dermatology, arselisborg Hospital, DK‐8000 Aarhus C, Denmark.</p></note><affiliation>Department of Dermatology, Marselisborg Hospital, University of Aarhus, Denmark</affiliation></author></analytic><monogr><title level="j">British Journal of Dermatology</title><idno type="pISSN">0007-0963</idno><idno type="eISSN">1365-2133</idno><idno type="DOI">10.1111/(ISSN)1365-2133</idno><imprint><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK</pubPlace><date type="published" when="1988-09"></date><biblScope unit="volume">119</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="321">321</biblScope><biblScope unit="page" to="325">325</biblScope></imprint></monogr><idno type="istex">350F372AD0F42DCE0960A56C8EF60D85E9DF046B</idno><idno type="DOI">10.1111/j.1365-2133.1988.tb03224.x</idno><idno type="ArticleID">BJD321</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>1988</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Twenty‐four psoriatic patients on methotrexate were studied with liver biopsies and serum measurements of aminoterminal propeptide of type III procollagen (PHI NP). All but one of nine patients with scrum levels of PHI NP above the normal range had liver fibrosis or cirrhosis and no normal liver biopsies were obtained in this group. In contrast, nine normal liver biopsies and two biopsies with minimal fibrosis were found among the 15 patients with normal serum levels of PHI NP. The study indicates that aminoterminal propeptide of type III procollagen can be utilized as a valuable non‐invasive marker of fibrogenesis in the liver. This analysis is not specific for the liver, but it seems that the number of liver biopsies probably can be reduced in psoriatics on methotrexate who have normal levels of PHI NP.</p></abstract></profileDesc><revisionDesc><change when="1988-09">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/350F372AD0F42DCE0960A56C8EF60D85E9DF046B/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Blackwell Publishing Ltd</publisherName><publisherLoc>Oxford, UK</publisherLoc></publisherInfo><doi origin="wiley" registered="yes">10.1111/(ISSN)1365-2133</doi><issn type="print">0007-0963</issn><issn type="electronic">1365-2133</issn><idGroup><id type="product" value="BJD"></id><id type="publisherDivision" value="ST"></id></idGroup><titleGroup><title type="main" sort="BRITISH JOURNAL OF DERMATOLOGY">British Journal of Dermatology</title></titleGroup></publicationMeta><publicationMeta level="part" position="09003"><doi origin="wiley">10.1111/bjd.1988.119.issue-3</doi><numberingGroup><numbering type="journalVolume" number="119">119</numbering><numbering type="journalIssue" number="3">3</numbering></numberingGroup><coverDate startDate="1988-09">September 1988</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="0032100" status="forIssue"><doi origin="wiley">10.1111/j.1365-2133.1988.tb03224.x</doi><idGroup><id type="unit" value="BJD321"></id></idGroup><countGroup><count type="pageTotal" number="5"></count></countGroup><eventGroup><event type="firstOnline" date="2006-07-29"></event><event type="publishedOnlineFinalForm" date="2006-07-29"></event><event type="xmlConverted" agent="Converter:BPG_TO_WML3G version:2.3.5 mode:FullText source:HeaderRef result:HeaderRef" date="2010-04-06"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:4.0.1" date="2014-03-15"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-15"></event></eventGroup><numberingGroup><numbering type="pageFirst" number="321">321</numbering><numbering type="pageLast" number="325">325</numbering></numberingGroup><correspondenceTo>Dr H.Zachariae, Department of Dermatology, arselisborg Hospital, DK‐8000 Aarhus C, Denmark.</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:BJD.BJD321.pdf"></link></linkGroup></publicationMeta><contentMeta><unparsedEditorialHistory>Accepted for publication 28 March 1988</unparsedEditorialHistory><countGroup><count type="referenceTotal" number="12"></count><count type="linksCrossRef" number="7"></count></countGroup><titleGroup><title type="main">Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis</title></titleGroup><creators><creator creatorRole="author" xml:id="cr1" affiliationRef="#a1"><personName><givenNames>J.</givenNames><familyName>RISTELI</familyName></personName></creator><creator creatorRole="author" xml:id="cr2" affiliationRef="#a3"><personName><givenNames>H.</givenNames><familyName>SØGAARD</familyName></personName></creator><creator creatorRole="author" xml:id="cr3" affiliationRef="#a2"><personName><givenNames>A.</givenNames><familyName>OIKARINEN</familyName></personName></creator><creator creatorRole="author" xml:id="cr4" affiliationRef="#a1"><personName><givenNames>L.</givenNames><familyName>RISTELI</familyName></personName></creator><creator creatorRole="author" xml:id="cr5" affiliationRef="#a2"><personName><givenNames>J.</givenNames><familyName>KARVONEN</familyName></personName></creator><creator creatorRole="author" xml:id="cr6" affiliationRef="#a4" corresponding="yes"><personName><givenNames>H.</givenNames><familyName>ZACHARIAE</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="a1" countryCode="FI"><unparsedAffiliation>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</unparsedAffiliation></affiliation><affiliation xml:id="a2" countryCode="FI"><unparsedAffiliation>Department of Dermatology, University of Oulu, Finland</unparsedAffiliation></affiliation><affiliation xml:id="a3" countryCode="DK"><unparsedAffiliation>Department of Pathology, Aarhus Kommunehospital, Denmark</unparsedAffiliation></affiliation><affiliation xml:id="a4" countryCode="DK"><unparsedAffiliation>Department of Dermatology, Marselisborg Hospital, University of Aarhus, Denmark</unparsedAffiliation></affiliation></affiliationGroup><abstractGroup><abstract type="main" xml:lang="en"><title type="main">SUMMARY</title><p>Twenty‐four psoriatic patients on methotrexate were studied with liver biopsies and serum measurements of aminoterminal propeptide of type III procollagen (PHI NP). All but one of nine patients with scrum levels of PHI NP above the normal range had liver fibrosis or cirrhosis and no normal liver biopsies were obtained in this group. In contrast, nine normal liver biopsies and two biopsies with minimal fibrosis were found among the 15 patients with normal serum levels of PHI NP. The study indicates that aminoterminal propeptide of type III procollagen can be utilized as a valuable non‐invasive marker of fibrogenesis in the liver. This analysis is not specific for the liver, but it seems that the number of liver biopsies probably can be reduced in psoriatics on methotrexate who have normal levels of PHI NP.</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis</title></titleInfo><name type="personal"><namePart type="given">J.</namePart><namePart type="family">RISTELI</namePart><affiliation>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">SØGAARD</namePart><affiliation>Department of Pathology, Aarhus Kommunehospital, Denmark</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A.</namePart><namePart type="family">OIKARINEN</namePart><affiliation>Department of Dermatology, University of Oulu, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L.</namePart><namePart type="family">RISTELI</namePart><affiliation>Collagen Research Unit, Biocentre and Department of Medical Biochemistry, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J.</namePart><namePart type="family">KARVONEN</namePart><affiliation>Department of Dermatology, University of Oulu, Finland</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H.</namePart><namePart type="family">ZACHARIAE</namePart><affiliation>Department of Dermatology, Marselisborg Hospital, University of Aarhus, Denmark</affiliation><description>Correspondence: Dr H.Zachariae, Department of Dermatology, arselisborg Hospital, DK‐8000 Aarhus C, Denmark.</description><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article"></genre><originInfo><publisher>Blackwell Publishing Ltd</publisher><place><placeTerm type="text">Oxford, UK</placeTerm></place><dateIssued encoding="w3cdtf">1988-09</dateIssued><edition>Accepted for publication 28 March 1988</edition><copyrightDate encoding="w3cdtf">1988</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="references">12</extent></physicalDescription><abstract lang="en">Twenty‐four psoriatic patients on methotrexate were studied with liver biopsies and serum measurements of aminoterminal propeptide of type III procollagen (PHI NP). All but one of nine patients with scrum levels of PHI NP above the normal range had liver fibrosis or cirrhosis and no normal liver biopsies were obtained in this group. In contrast, nine normal liver biopsies and two biopsies with minimal fibrosis were found among the 15 patients with normal serum levels of PHI NP. The study indicates that aminoterminal propeptide of type III procollagen can be utilized as a valuable non‐invasive marker of fibrogenesis in the liver. This analysis is not specific for the liver, but it seems that the number of liver biopsies probably can be reduced in psoriatics on methotrexate who have normal levels of PHI NP.</abstract><relatedItem type="host"><titleInfo><title>British Journal of Dermatology</title></titleInfo><genre type="Journal">journal</genre><identifier type="ISSN">0007-0963</identifier><identifier type="eISSN">1365-2133</identifier><identifier type="DOI">10.1111/(ISSN)1365-2133</identifier><identifier type="PublisherID">BJD</identifier><part><date>1988</date><detail type="volume"><caption>vol.</caption><number>119</number></detail><detail type="issue"><caption>no.</caption><number>3</number></detail><extent unit="pages"><start>321</start><end>325</end><total>5</total></extent></part></relatedItem><identifier type="istex">350F372AD0F42DCE0960A56C8EF60D85E9DF046B</identifier><identifier type="DOI">10.1111/j.1365-2133.1988.tb03224.x</identifier><identifier type="ArticleID">BJD321</identifier><recordInfo><recordContentSource>WILEY</recordContentSource><recordOrigin>Blackwell Publishing Ltd</recordOrigin></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Informatique/explor/ScrumV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002180 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002180 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Informatique
|area= ScrumV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:350F372AD0F42DCE0960A56C8EF60D85E9DF046B
|texte= Aminoterminal propeptide of type III procollagen in methotrexate‐induced liver fibrosis and cirrhosis
}}
| This area was generated with Dilib version V0.6.39. |  |